Ixabepilone
Tubulin Inhibitor
DB04845
Approved Indication
Investigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).
1
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Binding of Ixabepilone to beta-tubulins (e.g. beta-III tubulin) stabilizes microtubules. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. Like taxol, Ixabepilone binds to the αβ-tubulin heterodimer subunit. Once bound, the rate of αβ-tubulin dissociation decreases, thus stabilizing the microtubules.
Details
DrugBank ID
DB04845 ↗
Approval Date
2007-10-16
Molecular Weight
506.7 g/mol
Drug Class
Tubulin Inhibitor
ATC Codes
L01DC04
Synonyms
Aza-epothilone B, Azaepothilone B
PubChem
CID: 6445540 ↗
ChEMBL
CHEMBL1201752 ↗
SMILES
[H][C@]12C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]1(C)O2)C(\C)=C\C1=CSC(C)=N1
ADMET Profile
Computing properties…